CONAVI MEDICAL CORP (CNVI.CA) Fundamental Analysis & Valuation
TSX-V:CNVI • CA2059531020
Current stock price
0.37 CAD
+0.01 (+2.78%)
Last:
This CNVI.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. CNVI.CA Profitability Analysis
1.1 Basic Checks
- In the past year CNVI has reported negative net income.
- In the past year CNVI has reported a negative cash flow from operations.
- CNVI had negative earnings in 4 of the past 5 years.
- In the past 5 years CNVI reported 4 times negative operating cash flow.
1.2 Ratios
- CNVI has a Return On Assets (-164.51%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -164.51% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 107.51%, CNVI belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
- CNVI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 107.51% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. CNVI.CA Health Analysis
2.1 Basic Checks
- CNVI does not have a ROIC to compare to the WACC, probably because it is not profitable.
- CNVI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- CNVI has an Altman-Z score of -29.74. This is a bad value and indicates that CNVI is not financially healthy and even has some risk of bankruptcy.
- CNVI's Altman-Z score of -29.74 is in line compared to the rest of the industry. CNVI outperforms 46.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -29.74 |
ROIC/WACCN/A
WACC9.5%
2.3 Liquidity
- CNVI has a Current Ratio of 0.60. This is a bad value and indicates that CNVI is not financially healthy enough and could expect problems in meeting its short term obligations.
- With a Current ratio value of 0.60, CNVI perfoms like the industry average, outperforming 53.33% of the companies in the same industry.
- A Quick Ratio of 0.60 indicates that CNVI may have some problems paying its short term obligations.
- CNVI has a Quick ratio of 0.60. This is comparable to the rest of the industry: CNVI outperforms 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.6 | ||
| Quick Ratio | 0.6 |
3. CNVI.CA Growth Analysis
3.1 Past
- CNVI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 76.95%, which is quite impressive.
- Looking at the last year, CNVI shows a very negative growth in Revenue. The Revenue has decreased by -91.82% in the last year.
- The Revenue for CNVI have been decreasing by -30.88% on average. This is quite bad
EPS 1Y (TTM)76.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.93%
Revenue 1Y (TTM)-91.82%
Revenue growth 3Y-30.88%
Revenue growth 5YN/A
Sales Q2Q%-97.48%
3.2 Future
- The Earnings Per Share is expected to grow by 17.03% on average over the next years. This is quite good.
- Based on estimates for the next years, CNVI will show a very strong growth in Revenue. The Revenue will grow by 60.40% on average per year.
EPS Next Y50%
EPS Next 2Y25.5%
EPS Next 3Y17.86%
EPS Next 5Y17.03%
Revenue Next Year-34.34%
Revenue Next 2Y17.31%
Revenue Next 3Y44.8%
Revenue Next 5Y60.4%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. CNVI.CA Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for CNVI. In the last year negative earnings were reported.
- Also next year CNVI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- CNVI's earnings are expected to grow with 17.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.5%
EPS Next 3Y17.86%
5. CNVI.CA Dividend Analysis
5.1 Amount
- No dividends for CNVI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CNVI.CA Fundamentals: All Metrics, Ratios and Statistics
TSX-V:CNVI (3/24/2026, 7:00:00 PM)
0.37
+0.01 (+2.78%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-26 2026-02-26
Earnings (Next)05-26 2026-05-26
Inst Owners0.24%
Inst Owner ChangeN/A
Ins Owners0.16%
Ins Owner ChangeN/A
Market Cap38.29M
Revenue(TTM)706.00K
Net Income(TTM)-16.19M
Analysts80
Price Target1.02 (175.68%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 54.24 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.25
EYN/A
EPS(NY)-0.17
Fwd EYN/A
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.2
OCFYN/A
SpS0.01
BVpS-0.2
TBVpS-0.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -164.51% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 107.51% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 36.03% | ||
| Cap/Sales | 40.37% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.6 | ||
| Quick Ratio | 0.6 | ||
| Altman-Z | -29.74 |
F-Score1
WACC9.5%
ROIC/WACCN/A
Cap/Depr(3y)85.27%
Cap/Depr(5y)122.76%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.93%
EPS Next Y50%
EPS Next 2Y25.5%
EPS Next 3Y17.86%
EPS Next 5Y17.03%
Revenue 1Y (TTM)-91.82%
Revenue growth 3Y-30.88%
Revenue growth 5YN/A
Sales Q2Q%-97.48%
Revenue Next Year-34.34%
Revenue Next 2Y17.31%
Revenue Next 3Y44.8%
Revenue Next 5Y60.4%
EBIT growth 1Y-322.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-154.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-154.87%
OCF growth 3YN/A
OCF growth 5YN/A
CONAVI MEDICAL CORP / CNVI.CA Fundamental Analysis FAQ
What is the fundamental rating for CNVI stock?
ChartMill assigns a fundamental rating of 1 / 10 to CNVI.CA.
What is the valuation status of CONAVI MEDICAL CORP (CNVI.CA) stock?
ChartMill assigns a valuation rating of 0 / 10 to CONAVI MEDICAL CORP (CNVI.CA). This can be considered as Overvalued.
How profitable is CONAVI MEDICAL CORP (CNVI.CA) stock?
CONAVI MEDICAL CORP (CNVI.CA) has a profitability rating of 1 / 10.
What is the expected EPS growth for CONAVI MEDICAL CORP (CNVI.CA) stock?
The Earnings per Share (EPS) of CONAVI MEDICAL CORP (CNVI.CA) is expected to grow by 50% in the next year.